Genenta Science SpA · NASDAQ:GNTA
Genenta Science SpA — Investor Presentation (April 2026)
26 slides from Genenta Science SpA's investor presentation, April 2026
Slide 1: Genenta Evolving into Saentra Forge
GENENTA EVOLVING INTO SAENTRA FORGE The Next-Generation Strategic Industrial Consolidator in Biotech, Defense, Aerospace, National Security. © 2026 Genenta Science. All rights reserved worldwide April 2026
Slide 2: Forward-Looking Statements and Other Notices
FORWARD-LOOKING STATEMENTS AND OTHER NOTICES Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of histor
Slide 3: Leadership
LEADERSHIP + 30 years of experience as Chief Financial Officer in various biopharmaceutical, Highly experienced executive with skills diagnostic, and life science companies, in strategic finance, restructuring and reorganization processes, internal including Biological Dynamics, GenMark Diagnostics
Slide 4: Genenta Transforming into Saentra Forge
GENENTA TRANSFORMING INTO SAENTRA FORGE In response to evolving market dynamics and strategic opportunities, Genenta Science S.p.A. (Nasdaq: GNTA) is embarking on a strategic transformation to evolve into a next-generation strategic industrial consolidator focused on acquiring privately held busines
Slide 5: The Strategic Pillars
THE STRATEGIC PILLARS The Company will be organized around key synergistic pillars BIOTECHNOLOGY DEFENSE AEROSPACE NATIONAL SECURITY built through strategic majority acquisitions, creating a diversified platform. 5
Slide 6: Defense, Aerospace, National Security
• DEFENSE • AEROSPACE • NATIONAL SECURITY
Slide 7: Defense, Aerospace, National Security
DEFENSE, AEROSPACE, NATIONAL SECURITY Genenta’s defense and advanced manufacturing pillar will be built through the acquisition of multiple privately held businesses operating across defense, aerospace and security sectors. Through this integration, the Company will seek to enhance these businesses
Slide 8: Defense
Genenta Science ‘oe* | * DEFENSE
Slide 9: ATC: Company Overview
ATC: COMPANY OVERVIEW ▪ ATC “Armi Tattiche Custom” is an Italian company founded in 2019. ATC designs, engineers, and manufactures high- precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories. Through vertical integration of design and through final quality assura
Slide 10: ATC Integration: Key Figures
ATC INTEGRATION: KEY FIGURES • Genenta has entered into a binding agreement according to which it will provide funding for ATC through a series of reserved capital increases, via a performance-based and staged acquisition to support operations with the ultimate goal of owning a controlling position
Slide 11: Aerospace
Genenta Science 4. | * AEROSPACE
Slide 12: Sophia High Tech: Company Overview
SOPHIA HIGH TECH: COMPANY OVERVIEW Sòphia HT S.r.l. is an Italian aerospace and defense engineering and manufacturing company. At its core, Sòphia HT builds the critical mechanical components of space and defense systems — the precision parts that hold rockets together, protect satellites in orbit,
Slide 13: Sophia HT Integration: Key Figures
SOPHIA HT INTEGRATION: KEY FIGURES Genenta has entered into a binding offer with Sòphia HT an Italian company manufacturing critical parts for Europe's space and defense programs, under which Genenta will fund Sòphia HT through two reserved capital increases, with the goal of reaching a controlling
Slide 14: Biotechnology
Genenta Science BIOTECHNOLOGY
Slide 15: Genenta: Developing a Potential First in Class Cell Therapy
GENENTA: DEVELOPING A POTENTIAL FIRST IN CLASS CELL THERAPY Temferon TM is a one-time cell therapy designed to break the tumor-induced Proprietary platform to immune suppression by enabling sustained targeted expression of therapeutic provide durable and payload inside the tumor microenvironment (TM
Slide 16: Survival Metrics in TEM-GBM Study Up to 3 Years
SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS Evaluable Patients Dosed with Temferon 25 Number of Patients survival > 1 year 19 (76%) Number of Patients survival > 2 years1 8 (32%) Number of Patients survival > 3 years 2 (8%) Survival rate at 1 and 2 years since first surgery compared favorably wi
Slide 17: Partnerships to Take to the Next Stage
PARTNERSHIPS TO TAKE TO THE NEXT STAGE The Company has reached key clinical milestones that it believes will now enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, an
Slide 18: Harnessing the Power of Stem Cells While Incorporating miRNA
HARNESSING THE POWER OF STEM CELLS WHILE INCORPORATING miRNA Use TEMs as vehicles to deliver IFN-⍺ into the TME Tie2-Expressing Monocytes (TEMs) Circulate low frequency Recruited into tumors Tie2 P/E Interferon-𝛂 126T TEMs in blood Tie2 Tie2 IFN-𝛂 Reprogramming TEMs Vessels Nuclei De Palma et al…
Slide 19: Temferon Delivers IFN-α Within the Tumor Microenvironment
TEMFERON DELIVERS IFN-⍺ WITHIN THE TUMOR MICROENVIRONMENT Single Temferon treatment potentially renders solid tumors visible to the immune system Tie2 monocytes coupled with miRNA126 TEMFERON AT A GLANCE Temferon Infusion of enable targeted payload delivery inside TEMFERON frozen and stored transduc
Slide 20: Temferon: Overcoming Immuno-Oncology Barriers
TEMFERON: OVERCOMING IMMUNO-ONCOLOGY BARRIERS VIA TARGETED, TUMOR-AGNOSTIC IMMUNE ACTIVATION SELECTIVE DELIVERY DEMONSTRATED PREVENT ACTIVATE IMMUNE WITHIN THE TUMOR DURABILITY SYSTEMIC TOXICITY SYSTEM MICROENVIRONMENT Genenta cell-based CD14 Tie2 macrophages (TEMs) Peripheral Blood platform (IFN-⍺
Slide 21: Preliminary Clinical Data in uMGMT GBM
PRELIMINARY CLINICAL DATA IN µMGMT GBM • Detectable and expectedly very low levels of IFN-⍺ (pg/ml range) in plasma; • Manageable safety profile, with adverse events commonly associated with autologous stem cell transplantation and glioblastoma; SAFETY AND • No dose limiting toxicities observed to d
Slide 22: Pierluigi Paracchi, CEO
PIERLUIGI PARACCHI, CEO pierluigi.paracchi@genenta.com www.genenta.com Via dell’Annunciata 31 - 20121 Milan, Italy © 2026 Genenta Science. All rights reserved worldwide
Slide 23: Appendix
APPENDIX © 2026 Genenta Science. All rights reserved worldwide
Slide 24: Board of Directors
BOARD OF DIRECTORS Dr. Galimi is a physician-executive with over Giacomo Paracchi is a Partner at LEXIA. 30 years of experience in healthcare R&D, His work primarily focuses on corporate including leadership roles in private and law, commercial contracts and corporate public biotechs as well as larg
Slide 25: Advisor
ADVISOR PAOLO SALVATO ATC Board member and Genenta Science advisor Paolo Salvato is part of ATC’s Board of Directors and he serves as Genenta Science advisor. Mr. Salvato previously served as Chief Executive Officer of Fiocchi Munizioni S.p.A. (CSG Group), where he led operational strengthening, int
Slide 26: Financial Profile
FINANCIAL PROFILE Cash & cash equivalents and marketable securities1 $ 33 MM Expected cash runway2 More than 12 months Number of shares outstanding3 23.4 MM Average volume4 721K shares 1 – December 31, 2025. 2 – For additional information see the Company’s Form 20-F filed with the SEC on March 31, 2